Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drugFirst approved 2013

Fetzima(Levomilnacipran Hcl)AbbVie Inc. logoABBV

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by AbbVie Inc.

$27.0M

Medicare cost, 2024

Medicare drug plans spent $27.0 million on Fetzima (levomilnacipran hcl) in 2024, for 39,239 prescriptions and refills filled by 5,787 patients. Ohio accounts for the most spending ($1.9 million, 7% of the total). It is made by AbbVie Inc. (ABBV).

Medicare cost, 2024

$27.0M

-7.7% from 2023

Prescriptions

39K

$689.21 per claim

Patients

5,787

5,863 prescribers

Total spending, 2024

$27.1M

$4,676.06 per patient

Questions and answers

How much does Medicare spend on Fetzima?

Medicare prescription drug plans paid $27.0M for Fetzima in 2024, for 39,239 prescriptions and refills to 5,787 patients (down 7.7% from 2023). The average cost per claim was $689.21.

Which state spends the most on Fetzima?

Ohio had the highest Medicare cost for Fetzima in 2024: $1.9M for 3,043 claims, followed by California ($1.9M).

Who prescribes Fetzima the most?

Alexander Pinkusovich, psychiatry in Brooklyn, NY, had the highest Medicare cost for Fetzima in 2024: 135 claims costing $65K.

Who makes Fetzima?

Fetzima is made by AbbVie Inc. (ABBV), listed in the Medicare spending data as Forest/Allergan.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Fetzima was $27.1M in 2024, after a high of $30.6M in 2020.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Fetzima, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Alexander Pinkusovich Brooklyn, NYPsychiatry13520$65K
Timothy R Rasmussen Waite Park, MNPsychiatry104Under 11$52K
Julia E Lansing Columbus, OHCertified Clinical Nurse Specialist75Under 11$45K
John C Ciaccio Moline, ILPsychiatry77Under 11$44K
Stephen L Dilts Jr. York, PAPsychiatry15Under 11$41K
Joseph Luzius Albuquerque, NMPsychiatry69Under 11$40K
Matthew A Bayer Menasha, WIPsychiatry58Under 11$36K
Pamela Schwartz Warsaw, INNurse Practitioner44Under 11$36K
Roy B del-Rosario Lancaster, CAPsychiatry60Under 11$36K
Francis S Penland Hickory, NCNurse Practitioner25Under 11$35K
Wendy L Corriveau Dearborn, MINurse Practitioner12Under 11$35K
Jennifer C Heath Fort Worth, TXPsychiatry & Neurology60Under 11$35K
Ryan M Bednar Medina, OHNurse Practitioner39Under 11$34K
Angela C Hammond Memphis, TNNurse Practitioner34Under 11$33K
Rebecca A Moore Madelia, MNNurse Practitioner53Under 11$32K
Shannon Harding Salt Lake City, UTNurse Practitioner30Under 11$32K
William Bara-Jimenez Kensington, MDNeurology46Under 11$30K
Tania C Martinez-Jimenez Bethlehem, PAPsychiatry21Under 11$30K
Joseph C Shanklin Clearwater, FLPsychiatry19Under 11$30K
Jonathan C Uecker New Brighton, MNPsychiatry48Under 11$29K
Lee S Spain Meadville, PAPsychiatry52Under 11$29K
Nicholas Tobin Longmeadow, MANurse Practitioner43Under 11$29K
Peter E Neifert Staples, MNPsychiatry44Under 11$28K
Alfred E Buxton Lafayette, LAPsychologist, Clinical47Under 11$28K
Sonia Motin Kalamazoo, MIPsychiatry3711$28K

Prescriber data by year

YearPrescribersClaimsPatientsCost
20226,70746,6636,681$29.8M
20236,36642,7106,276$29.3M
20245,86339,2395,787$27.0M

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Forest/AllerganABBV logoABBV39,287$27.1M

Medicaid spending by quarter

Amount reimbursed by state Medicaid programs, all states

Amount reimbursed

Codes

National drug codes (packages)
10
RxNorm concept IDs
1433217, 1433223, 1433227, 1433229, 1433233
Application numbers
NDA204168

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube